The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.
Jun Zhang
No relevant relationships to disclose
Dongsheng Wang
No relevant relationships to disclose
Guoqing Qian
No relevant relationships to disclose
Fakeng Liu
No relevant relationships to disclose
Mohammad Aminur Rahman
No relevant relationships to disclose
Sreevinas Nannapaneni
No relevant relationships to disclose
Xu Wang
No relevant relationships to disclose
Xianghong Peng
No relevant relationships to disclose
Zhuo Georgia Chen
No relevant relationships to disclose
Kwok-Kin Wong
No relevant relationships to disclose
Fadlo Raja Khuri
No relevant relationships to disclose
Wei Zhou
No relevant relationships to disclose
Dong Moon Shin
No relevant relationships to disclose